Philippe Beuzeboc Selected Research

Estramustine

7/2015	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
1/2012	A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
11/2010	A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
5/2009	Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
5/2005	Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Beuzeboc Research Topics

Disease

41	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 01/2002
30	Neoplasms (Cancer) 10/2022 - 04/2002
14	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2002
13	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2002
8	Carcinoma (Carcinomatosis) 10/2022 - 11/2003
6	Disease Progression 09/2020 - 05/2009
5	Pain (Aches) 03/2022 - 05/2009
5	Neutropenia 01/2021 - 02/2013
4	Renal Insufficiency (Renal Failure) 03/2012 - 09/2007
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 01/2004
3	Lung Neoplasms (Lung Cancer) 07/2015 - 01/2009
2	Fatigue 03/2022 - 01/2012
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2012
2	Hypertension (High Blood Pressure) 01/2022 - 11/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 09/2009
2	Febrile Neutropenia 05/2019 - 02/2013
2	Head and Neck Neoplasms (Head and Neck Cancer) 06/2015 - 01/2002
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2015 - 01/2011
2	Seminoma 02/2014 - 02/2003
2	Cardiotoxicity 06/2011 - 03/2007
2	Transitional Cell Carcinoma 07/2009 - 11/2005
1	Alopecia (Baldness) 03/2022
1	Edema (Dropsy) 03/2022
1	Digestive System Diseases 01/2022
1	Heart Failure 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Liver Failure 01/2022
1	Massive Hepatic Necrosis 01/2022
1	Thrombotic Microangiopathies 01/2022
1	Diarrhea 01/2021

Drug/Important Bio-Agent (IBA)

21	Docetaxel (Taxotere)FDA Link 03/2022 - 05/2005
17	AndrogensIBA 05/2019 - 11/2003
12	Hormones (Hormone)IBA 05/2019 - 11/2003
6	cabazitaxel FDA Link 03/2022 - 04/2011
6	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 10/2005
6	Pharmaceutical PreparationsIBA 01/2021 - 09/2007
6	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 05/2009
6	Trastuzumab (Herceptin)FDA Link 01/2017 - 05/2004
5	PlatinumIBA 10/2022 - 07/2009
5	AnthracyclinesIBA 01/2017 - 04/2002
5	Estramustine FDA Link 07/2015 - 05/2005
5	CreatinineIBA 12/2010 - 10/2005
4	Taxoids (Taxanes)IBA 03/2022 - 12/2010
4	Monoclonal AntibodiesIBA 01/2021 - 05/2004
4	Gemcitabine FDA Link 03/2016 - 10/2005
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2012
3	ErbB Receptors (EGF Receptor)IBA 01/2021 - 11/2003
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 07/2004
3	Prednisone (Sone)FDA LinkGeneric 12/2020 - 05/2005
3	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 12/2014
3	Abiraterone AcetateIBA 08/2015 - 07/2012
3	SaltsIBA 01/2015 - 03/2012
3	Mitoxantrone (Novantrone)FDA LinkGeneric 04/2011 - 05/2005
2	pembrolizumabIBA 10/2022 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2003
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2017
2	abirateroneIBA 12/2020 - 08/2015
2	Denosumab FDA Link 01/2019 - 11/2012
2	Diphosphonates (Bisphosphonates)IBA 01/2019 - 05/2014
2	Bevacizumab (Avastin)FDA Link 01/2017 - 11/2015
2	Alkaline PhosphataseIBA 08/2015 - 02/2012
2	enzalutamideIBA 08/2015 - 01/2014
2	Zoledronic Acid (Zometa)FDA Link 05/2014 - 11/2012
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2014 - 02/2013
2	Etoposide (VP 16)FDA LinkGeneric 02/2014 - 07/2012
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2012 - 07/2004
2	ZD4054IBA 10/2010 - 05/2009
2	Pain-FreeIBA 10/2010 - 05/2009
2	Endothelin A ReceptorIBA 10/2010 - 05/2009
2	human ERBB2 proteinIBA 03/2007 - 05/2004
1	AntibodiesIBA 01/2022
1	IpilimumabIBA 01/2022
1	Sunitinib (Sutent)FDA Link 01/2022
1	NivolumabIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	Lipase (Acid Lipase)FDA Link 01/2022
1	VaccinesIBA 01/2022
1	sacituzumab govitecanIBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2021
1	Panitumumab (Vectibix)FDA Link 01/2021
1	EnzymesIBA 12/2020
1	olaparibIBA 12/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2020

Therapy/Procedure

31	Drug Therapy (Chemotherapy) 03/2022 - 01/2002
28	Therapeutics 10/2022 - 01/2003
21	Castration 03/2022 - 05/2009
7	Radiotherapy 10/2021 - 01/2004
3	Cystectomy 01/2017 - 01/2004
3	Adjuvant Chemotherapy 01/2017 - 07/2006
2	Duration of Therapy 01/2020 - 04/2015
2	Chemoradiotherapy 06/2015 - 01/2004
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 06/2012 - 09/2009
2	Lymph Node Excision (Lymph Node Dissection) 01/2012 - 02/2003
2	Drug Tapering 12/2010 - 10/2009
2	Aftercare (After-Treatment) 05/2009 - 04/2002
1	Immunotherapy 01/2022
1	Injections 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021